Cancer NGS Testing Platform Market Share Driven by Liquid Biopsy Advancements and Precision Oncology Demand | Valuates Reports

Cancer NGS Testing Platform Market Size
The global market for Cancer NGS Testing Platform was valued at US$ 527 million in the year 2024 and is projected to reach a revised size of US$ 1381 million by 2031, growing at a CAGR of 15.0% during the forecast period.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-11K19880/Global_Cancer_NGS_Testing_Platform_Market_Research_Report_2025

The Cancer NGS Testing Platform Market is experiencing significant market growth as next-generation sequencing (NGS) technologies become increasingly important in oncology diagnostics and precision medicine. NGS-based cancer testing platforms enable comprehensive genomic analysis of tumor-related genetic alterations, allowing clinicians and researchers to detect cancer at early stages, identify actionable mutations, and monitor disease progression. The growing adoption of liquid biopsy technologies, increasing cancer prevalence worldwide, and rising demand for personalized treatment strategies are shaping key market trends and contributing to the expansion of the global market size.

Based on type segmentation, cfDNA methylation sequencing represents a major market segment as it enables the detection of cancer-specific methylation patterns in circulating cell-free DNA (cfDNA). This technology is widely used in early cancer detection and screening applications due to its high sensitivity and ability to identify epigenetic changes associated with tumor development. Whole genome sequencing based on cfDNA fragmentation end characteristics and copy number variation (CNV) analysis is another important segment in the market. This advanced approach analyzes fragmentation patterns and structural variations in circulating DNA fragments, providing deeper insights into tumor biology and supporting non-invasive cancer diagnostics.

In terms of application, hospitals represent a significant market share in the cancer NGS testing platform market as healthcare providers increasingly adopt genomic testing technologies for cancer diagnosis, treatment planning, and patient monitoring. Clinics also contribute to the market size as precision oncology services expand into specialized cancer treatment centers. Medical laboratories play a crucial role in the market by performing high-throughput genomic testing and providing diagnostic services for healthcare institutions. Meanwhile, university laboratories and research institutes continue to drive innovation in cancer genomics through academic research, clinical trials, and biomarker discovery programs.

Leading companies such as Illumina, GRAIL, and Exact Sciences hold strong market share due to their advanced genomic sequencing technologies and innovative cancer diagnostic platforms. Other major industry participants include Guardant Health, Foundation Medicine, BGI Genomics, Burning Rock Biotech, Berry Oncology, Genetron Health, Hangzhou New Horizon Health Technology, Jiangsu Huayuan Biotechnology, and Yeasen Biotechnology. These companies continue to invest heavily in genomic sequencing technologies, cancer biomarker research, and advanced diagnostic platforms to strengthen their positions in the competitive oncology diagnostics landscape.

Regionally, North America dominates the cancer NGS testing platform market share due to its advanced healthcare infrastructure, strong adoption of precision medicine technologies, and significant investment in cancer research. Europe also represents an important market supported by increasing genomic research initiatives and expanding molecular diagnostics capabilities. Meanwhile, Asia-Pacific is witnessing rapid market growth as countries such as China, Japan, South Korea, and India continue to invest in biotechnology research, genomic medicine, and cancer diagnostics infrastructure. Emerging markets in Latin America and the Middle East are also gradually adopting advanced cancer testing technologies as healthcare systems modernize and awareness of early cancer detection increases. The overall market forecast remains highly positive as advancements in next-generation sequencing technologies, increasing demand for non-invasive cancer diagnostics, and the growing focus on personalized oncology treatments continue to drive long-term growth in the cancer NGS testing platform market.

Segment by Type

• cfDNA Methylation Sequencing
• Whole Genome Sequencing Based On cfDNA Fragmentation End Characteristics and CNV

Segment by Application

• Hospitals
• Clinics
• Medical Laboratories
• University Laboratories
• Others

By Company

GRAIL, Exact Sciences, Guardanthealth, Akery, Foundation Medicine, Illumina, Inc., Hangzhou New Horizon Health Technology Co., Ltd., Berry Oncology Co., Ltd., Genetron Health (Beijing) Co., Ltd., Yeasen, Guangzhou Burning Rock Dx Co., Ltd., BGI Genomics Co., Ltd., Jiangsu Huayuan Biotechnology Co., Ltd.

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-11K19880/global-cancer-ngs-testing-platform

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.